Teva And Alvotech Celebrate Interchangeability For US Ustekinumab
As Biocon Claims Advantage By Securing Market Access Agreements
The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.
